A cancer patient who is on cisplatin therapy develops severe vomiting on the 1st day of treatment, drug indicated to treat this is:
**Core Concept**
The question is testing the understanding of the pathophysiology of chemotherapy-induced nausea and vomiting (CINV) and the role of specific pharmacological agents in managing this condition. CINV is a complex process involving the activation of various neurotransmitters and receptors in the central nervous system (CNS) and the gastrointestinal tract.
**Why the Correct Answer is Right**
Cisplatin is a highly emetogenic chemotherapy agent that activates the vagus nerve, leading to the release of acetylcholine, which then stimulates the area postrema in the CNS. This results in the activation of the vomiting center, characterized by the release of neurotransmitters such as dopamine, serotonin, and substance P. The correct answer, **metoclopramide**, is a dopamine antagonist that blocks the action of dopamine at the D2 receptors in the chemoreceptor trigger zone (CTZ) of the CNS, thereby preventing the initiation of the vomiting reflex. Metoclopramide also has prokinetic effects, enhancing gastric emptying and reducing nausea.
**Why Each Wrong Option is Incorrect**
* **Option A:** Ondansetron is a serotonin 5-HT3 receptor antagonist that is effective in preventing CINV, but it is not the best choice for treating severe vomiting on the 1st day of treatment with cisplatin.
* **Option B:** Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist that is used in combination with ondansetron and dexamethasone for the prevention of CINV, but it is not the primary treatment for acute severe vomiting.
* **Option D:** Haloperidol is a dopamine antagonist, but it is not typically used for the treatment of CINV due to its sedative and extrapyramidal side effects.
**Clinical Pearl / High-Yield Fact**
When treating CINV, it is essential to use a combination of antiemetic agents that target different pathways, such as dopamine antagonists (e.g., metoclopramide), serotonin 5-HT3 receptor antagonists (e.g., ondansetron), and substance P/NK1 receptor antagonists (e.g., aprepitant).
**Correct Answer:** C. Metoclopramide